Friday, June 30, 2017

Original Article The clinical roles of rheumatoid factor in the treatment of chronic hepatitis C infection

Int J Clin Exp Med 2017;10(6):9456-9462 www.ijcem.com /ISSN:1940-5901/IJCEM0049611

Original Article The clinical roles of rheumatoid factor in the treatment of chronic hepatitis C infection
Wei-Ming Chen1,2,3*, Kao-Chi Chang1*, Ko-Ming Lin2,3,4, Kuo-Liang Wei1,3, Pey-Jium Chang2, Te-Sheng Chang1,2,3, Chein-Heng Shen1, Shui-Yi Tung1,3

Received January 24, 2017; Accepted April 28, 2017; Epub June 15, 2017; Published June 30, 2017

Download Full Text Article

Abstract: Objective:
The hepatitis C virus infection is associated with arthritis. However, the clinical roles of the rheumatoid factor in patients who received anti-viral treatment are not as clear.

Methods: To identify the association between the rheumatoid factor and the treatment response in hepatitis C virus infected patients, we enrolled patients who received anti-viral treatment with peg-interferon plus weight-based ribavirin according to response guided therapy. Patients who had a mix type hepatitis C infection, any autoimmune diseases, hepatitis B co-infection or intolerance to the side effects of therapy were excluded. Patients were divided into a rheumatoid factor (RF) positive (>20 IU/ml) group and a rheumatoid negative group. The patient’s characteristics, treatment response, dynamic changing of the rheumatoid factor and factors influenced the sustained virus response (SVR) of therapy, which were analyzed.

Results: A total of 271 patients completed the anti-viral treatment and analysis. The positive rate of the rheumatoid factor is 47.23% (128/271). In the RF positive group, the SVR rate was 82.8%, 71.0%, 96.6% for overall, genotype 1 infected, and non-genotype 1 infected patients, respectively. In the RF negative group, the SVR rate was 77.6%, 66.7%, 91.9% for overall, genotype 1 infected, and non-genotype 1 infected patients, respectively. There is a trend toward a higher SVR rate in RF positive patients, but no statistical difference was noted. In RF positive patients who achieved SVR, the RF values reduced significantly (56.4±78.0 vs. 39.4±39.6, P<0.001) after treatment but not in the non-SVR group (43.8±25.9 vs. 31.7±13.5, P=0.074). In the RF negative group, 37.8% and 34.4% of the patients’ RF became positive after treatment in the SVR group and in the non-SVR group. A lower virus load (<800,000 copies/ml), non-genotype 1 infection, alanine aminotransferase (ALT) rapid normalization, rapid viral response (RVR) and complete early viral response (cEVR) are significant predictive factors associated with SVR. The present or dynamic change of the rheumatoid factor cannot predict the effect of the treatment response.

Conclusions: The rheumatoid factor was positive in 47% of the chronic hepatitis C virus infected patients. In the RF positive group, the treatment response was better but not statistically significant. After treatment, the RF value was significantly reduced in cured patients.
Continue reading....

Recommended Reading
An Overview of Extrahepatic Manifestations of Hepatitis
A patient friendly fact sheet explaining conditions associated with HCV including symptoms.
The hepatitis C virus mainly affects the liver, but there are many other conditions that are associated with hepatitis C.  Extrahepatic manifestation means diseases or conditions that affect organs other than the liver.  Extrahepatic manifestations of hepatitis C can be found in the skin, eyes, joints, immune system, nervous system and kidneys.  Some of these conditions – cryoglobulinemia, for example – are somewhat more common and well documented, while others are infrequent or their association with hepatitis C has not yet been proven.

Recently published in Journal of Advanced Research is a nice collection of review articles on the extrahepatic manifestations of HCV.
Volume 8, Issue 2, March 2017, Pages 85–87

In The News
Lower Risk of Hep C Extrahepatic Manifestations With Sustained Virological Response
Patients who achieved a sustained virological response (SVR) to interferon-based antiviral therapy for hepatitis C virus (HCV) had a reduced risk of extrahepatic manifestations, according to a retrospective cohort study.

No comments:

Post a Comment